CALCIUM ABSORPTION IN NEONATES FED WITH MOTHER'S MILK FORTIFIED WITH A DONOR
用捐赠者强化母乳喂养的新生儿的钙吸收
基本信息
- 批准号:7950643
- 负责人:
- 金额:$ 0.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-01 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:BiologicalBiological AvailabilityBody CompositionBody WeightBone GrowthBreast FeedingCalciumCattleClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDataDevelopmentEffectivenessFundingGrantGrowthHuman MilkIndividualInfantInfectionInfection preventionInstitutionIntakeMilkMilk ProteinsMineralsMothersNecrotizing EnterocolitisNeonatalNutrientNutritional RequirementsOutcomePhysiologic calcificationPowder dose formPremature InfantProteinsProtocols documentationResearchResearch PersonnelResourcesRiskSourceTestingUnited States National Institutes of HealthVery Low Birth Weight Infantbasebonecalcium absorptiondesignefficacy trialfeedingmeetingsneonatenutritionpremature
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Breast milk is considered the nutrition of choice for infants, including premature infants in the Neonatal ICU (NICU). In the case of very low birth weight (VLBW) infants, this milk is generally supplemented with a human milk fortifier (HMF) in order to provide the additional nutrients that these babies require. We propose to investigate a HMF made from pasteurized donor human milk, in particular regarding calcium absorption, growth, bone mineral status, body composition, and feeding tolerance. We hypothesize that these study parameters will result in adequate outcomes with the use of the donor milk based HMF.
The use of a human milk fortifier made from pasteurized donor human milk will provide adequate calcium absorption to preterm infants. In addition, this new fortifier will provide adequate growth and bone mineralization.
SPECIFIC AIMS: Primary Aim: To determine calcium absorption in premature infants fed mother's own milk fortified with pasteurized donor human milk fortifier.
Secondary Aims: (1) To evaluate the growth, bone mineral status, and body composition of premature infants fed mother's own milk fortified with pasteurized donor human milk fortifier, and, (2) To assess feeding tolerance (pilot data) in infants fed mother's own milk fortified with pasteurized donor human milk.
BACKGROUND AND SIGNIFICANCE:Infants who are premature and below about 2.0 kg have unique nutritional requirements including a need for higher intakes of protein and minerals on a body weight basis than full-term infants. Routine cow's milk based formula as well as mother's own milk are insufficient to meet those requirements. Therefore, virtually all infants < 2.0 kg are fed either their own mother's milk fortified with a cow's milk based powdered infant fortifier or, if the mother does not proved an adequate volume of her milk or chooses not to breast feed, they will receive a cow's milk based formula designed for premature infants. Although these products have been used for many years and have been shown to be relatively safe and effective, persistent concerns exist regarding an increased risk of infections and necrotizing enterocolitis (NEC) in premature infants who receive cow's milk based feeding products. It has been shown that feeding tolerance is enhanced and NEC risk is decreased in infants receiving human milk, although the specific benefits of avoiding all cow's milk protein are uncertain.
The possibility of safely and effectively avoiding the use of all cow's milk based products has recently become possible due to the development of a human milk-based fortifier made from pasteurized donor human milk (Prolact-plus, Prolacta Bioscience, Monrovia, CA). The effectiveness of this fortifier in preventing infections and NEC will be tested in a multi-center trial in 2007. To date, it has been used only in individual cases and in smaller growth trials. However, the biological equivalence of using this newer donor milk product is not known. Specifically, the appropriate level and bioavailability of calcium, which is critical for preterm infants has not been tested from a donor milk product such as the Prolact-Plus. Therefore, we are conducting this study to determine the calcium and bone mineral effects of this product, using a protocol similar to that which will be used in the upcoming multi-center efficacy trial.
该子项目是利用该技术的众多研究子项目之一
资源由 NIH/NCRR 资助的中心拨款提供。子项目及
研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金,
因此可以在其他 CRISP 条目中表示。列出的机构是
对于中心来说,它不一定是研究者的机构。
母乳被认为是婴儿的首选营养品,包括新生儿重症监护病房 (NICU) 中的早产儿。对于极低出生体重 (VLBW) 婴儿,这种牛奶通常会添加母乳强化剂 (HMF),以提供这些婴儿所需的额外营养。我们建议研究由巴氏灭菌的捐赠母乳制成的 HMF,特别是在钙吸收、生长、骨矿物质状况、身体成分和喂养耐受性方面。我们假设这些研究参数将通过使用基于 HMF 的捐赠乳产生足够的结果。
使用由巴氏灭菌的捐赠母乳制成的母乳强化剂将为早产儿提供足够的钙吸收。此外,这种新的强化剂将提供足够的生长和骨矿化。
具体目标: 主要目标:确定用巴氏灭菌捐赠母乳强化剂强化母乳喂养的早产儿的钙吸收情况。
次要目标:(1) 评估用巴氏灭菌捐赠母乳强化剂喂养的母乳喂养的早产儿的生长、骨矿物质状况和身体成分,以及 (2) 评估用母乳喂养的婴儿的喂养耐受性(试点数据)用巴氏灭菌的捐赠母乳强化自己的母乳。
背景和意义:早产儿和体重低于 2.0 公斤的婴儿具有独特的营养需求,包括与足月婴儿相比,基于体重需要摄入更多的蛋白质和矿物质。常规的基于牛奶的配方奶以及母亲自己的乳汁不足以满足这些要求。因此,几乎所有体重 < 2.0 公斤的婴儿都喂食自己的母乳,其中添加了以牛奶为基础的婴儿奶粉强化剂,或者,如果母亲不能证明其母乳量足够或选择不进行母乳喂养,他们将接受母乳喂养。专为早产儿设计的牛奶配方奶粉。尽管这些产品已使用多年,并且已被证明相对安全有效,但人们一直担心接受牛奶喂养产品的早产儿感染和坏死性小肠结肠炎 (NEC) 的风险增加。研究表明,接受母乳的婴儿喂养耐受性增强,NEC 风险降低,尽管避免使用所有牛奶蛋白的具体益处尚不确定。
最近,由于开发了一种由巴氏灭菌捐赠母乳制成的母乳强化剂(Prolact-plus,Prolacta Bioscience,蒙罗维亚,加利福尼亚州),安全有效地避免使用所有牛奶产品的可能性已成为可能。这种强化剂预防感染和 NEC 的有效性将于 2007 年在一项多中心试验中进行测试。迄今为止,它仅在个别病例和小型生长试验中使用。然而,使用这种新型捐赠奶制品的生物等效性尚不清楚。具体而言,对于早产儿至关重要的钙的适当水平和生物利用度尚未通过 Prolact-Plus 等捐赠乳制品进行测试。因此,我们正在进行这项研究,以确定该产品的钙和骨矿物质作用,使用的方案类似于即将在即将到来的多中心功效试验中使用的方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN A ABRAMS其他文献
STEVEN A ABRAMS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN A ABRAMS', 18)}}的其他基金
EVALUATION OF THE USE OF DONOR HUMAN MILK FOR INFANTS WITH ABDOMINAL WALL DEFECT
腹壁缺陷婴儿使用供者母乳的评估
- 批准号:
8356736 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
COMPASSIONATE USE OF AN INTRAVENOUS FAT EMULSION COMPRISED OF FSIH OIL IN THE TR
在 TR 中善意地使用由 FSIH 油组成的静脉脂肪乳剂
- 批准号:
8356700 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
EVALUATION OF CALCIUM, VITAMIN D, MAGNESIUM AND ZINC ABSORPTION IN HEALTHY
评估钙、维生素 D、镁和锌的健康吸收情况
- 批准号:
8356713 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
QUALITY IMPROVEMENT PROJECT - EVALUATION OF CURRENT STANDARD OF CARE
质量改进项目 - 评估当前护理标准
- 批准号:
8356752 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
VITAMIN D STATUS AND IMPACT ON BONE MINERALIZATION IN HUMAN MILK FED HISPANIC
母乳喂养的西班牙裔人的维生素 D 状况及其对骨矿化的影响
- 批准号:
8356696 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
ZINC AND COPPER EXCRETION AND ABSORPTION IN INFANTS WITH OSTOMIES
造口婴儿的锌和铜排泄和吸收
- 批准号:
8356699 - 财政年份:2010
- 资助金额:
$ 0.24万 - 项目类别:
Enhancing Dietary Iron and Zinc Bioavailability in Indian Children
提高印度儿童膳食铁和锌的生物利用度
- 批准号:
7665615 - 财政年份:2009
- 资助金额:
$ 0.24万 - 项目类别:
EVALUATION OF CALCIUM, VITAMIN D, MAGNESIUM AND ZINC ABSORPTION IN HEALTHY
评估钙、维生素 D、镁和锌的健康吸收情况
- 批准号:
8166738 - 财政年份:2009
- 资助金额:
$ 0.24万 - 项目类别:
CALCIUM ABSORPTION IN NEONATES FED WITH MOTHER'S MILK FORTIFIED WITH A DONOR
用捐赠者强化母乳喂养的新生儿的钙吸收
- 批准号:
8166693 - 财政年份:2009
- 资助金额:
$ 0.24万 - 项目类别:
EVALUATION OF THE USE OF DONOR HUMAN MILK FOR INFANTS WITH ABDOMINAL WALL DEFECT
腹壁缺陷婴儿使用供者母乳的评估
- 批准号:
8166750 - 财政年份:2009
- 资助金额:
$ 0.24万 - 项目类别:
相似国自然基金
脂肪酸甘油酯/磷脂对乳液界面演变及营养素生物利用度的调控机制
- 批准号:32372325
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于果蔬胞外囊泡传递体系负载疏水多酚及其生物利用度增效机制
- 批准号:32302070
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α-乳白蛋白姜黄素纳米复合物通过PepT1-溶酶体提高生物利用度对镉致动脉粥样硬化的干预作用机制研究
- 批准号:82373600
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
植物三萜羽扇豆醇高生物利用度纳米超分子自组装结构的详细解析及提升机制研究
- 批准号:32300336
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于神经血管单元研究参附注射液抑制eNOS解耦增加NO生物利用度抗血管性痴呆的机制
- 批准号:82360880
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Physiology of Lifespan Extension and Metabolic Hormesis with Riboflavin Depletion
核黄素消耗延长寿命和代谢兴奋作用的生理学
- 批准号:
10663638 - 财政年份:2023
- 资助金额:
$ 0.24万 - 项目类别:
Physiology of Lifespan Extension and Metabolic Hormesis with Riboflavin Depletion
核黄素消耗延长寿命和代谢兴奋作用的生理学
- 批准号:
10663638 - 财政年份:2023
- 资助金额:
$ 0.24万 - 项目类别:
PAHs: New Technologies and Emerging Health Risks
PAH:新技术和新出现的健康风险
- 批准号:
10415776 - 财政年份:2022
- 资助金额:
$ 0.24万 - 项目类别:
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease
母婴二人的动脉僵硬度:预防心血管疾病的生命全程方法
- 批准号:
10581158 - 财政年份:2021
- 资助金额:
$ 0.24万 - 项目类别:
Gut Bacteriophage Correspondence with Inflammation and Clinical Dietary Interventions
肠道噬菌体与炎症和临床饮食干预的对应关系
- 批准号:
10614428 - 财政年份:2021
- 资助金额:
$ 0.24万 - 项目类别: